This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New Strong Sell Stocks for December 7th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) witnesses dismal segmental performance in Q3; 2018 guidance lowered.
Dentsply International (XRAY) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of -15.56% and -2.56%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
BioLife (BLFS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
BioLife (BLFS) is likely to gain from solid segmental revenues in Q3.
Analysts Estimate Dentsply International (XRAY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can R&D Focus Drive DENTSPLY SIRONA's (XRAY) Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) focus on R&D and strategic buyouts to drive Q2 results.
DENTSPLY Launches Azento, Improves Digital Implant Workflow
by Zacks Equity Research
DENTSPLY's (XRAY) Azento is a unique dental platform that will help dentists select the best-fitting implant, optimal implant positioning and feasible healing environment.
Dentsply (XRAY) Down 2.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PDCO or XRAY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PDCO vs. XRAY: Which Stock Is the Better Value Option?
Here's Why You Should Dump DENTSPLY (XRAY) Stock Right Now
by Zacks Equity Research
DENTSPLY (XRAY) incurs goodwill and intangible impairment charge. A lowered guidance is a concern.
DENTSPLY (XRAY) Beats on Q2 Earnings, Lowers 2018 Guidance
by Zacks Equity Research
DENTSPLY (XRAY) gains from solid year-over-year international revenue growth in Q2; high impairment charges in the quarter mars results.
DENTSPLY (XRAY) Q2 Earnings Beat Estimates, Sales Rise Y/Y
by Zacks Equity Research
DENTSPLY (XRAY) reported adjusted earnings of 60 cents per share, which came above the Zacks Consensus Estimate by a penny and was higher than earnings of 65 cents in the year-ago quarter.
Will Dentsply (XRAY) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Dentsply (XRAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Dental Stocks to Top Earnings Estimates This Season
by Zacks Equity Research
On upbeat consumer sentiment and increased business investments, the dental supplies industry appears to be in the pink of health now.
Why Dentsply (XRAY) Could Beat Earnings Estimates Again
by Zacks Equity Research
Dentsply (XRAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in the Cards for Humana (HUM) Stock in Q2 Earnings?
by Zacks Equity Research
Humana's (HUM) second quarter is likely to gain traction from solid individual Medicare Advantage membership growth.
Can R&D Focus Drive DENTSPLY SIRONA's (XRAY) Q2 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) continued focus on research and development and strategic buyouts are likely to drive Q2 results.
Here's Why You Should Hold Onto DENTSPLY SIRONA Stock Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) gains from its increasing focus on innovation while a lowered earnings guidance for 2018 raises concern.
DENTSPLY (XRAY) Down 11.8% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
DENTSPLY (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Sell DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
A rapidly changing healthcare environment in the United States, sluggish first quarter, declining margins and foreign exchange headwinds continue to hurt DENTSPLY SIRONA (XRAY).
DENTSPLY (XRAY) Beats Q1 Earnings Estimates, Lowers View
by Zacks Equity Research
Strong performance in Europe and Rest of World boosts DENTAPLY's (XRAY) performance in Q1. However, a lowered guidance indicates looming concerns.
Can Overall Growth Drive Henry Schein's (HSIC) Q1 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) likely to gain on strength across all business segments in Q1.
What's in Store for DENTSPLY (XRAY) This Earnings Season?
by Zacks Equity Research
DENTSPLY's (XRAY) CAD/CAM unit is likely to drive the top line in Q1. Product innovations and strong R&D prospects are also likely to drive growth.
Henry Schein Ties Up With Internet Brands to Boost Dental Arm
by Zacks Equity Research
Henry Schein (HSIC) banks on part of its strategic plan, digital dentistry. In this regard, its latest joint venture with Internet Brands buoys optimism.
New Strong Sell Stocks for April 9th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: